Zhejiang Jiangxin Pharmaceutical is engaged in the production and sale of tablet, hard capsule, granula, dry suspension, large-volume injection, powder injection and raw material medicines, and chemical intermediary products; the development of new products and technology transfer; and the import and export businesses. Co. offers cyclopropyl carboxylic acid, ciprofloxacin lactate, ciprofloxacin, ciprofloxacin hydrochloride, levofloxacin hydrochloride and enrofloxaxcin. Through its subsidiaries, Co. is also engaged in the research, development and production of Chinese medicine, natural medicine, biological medicine, chemical medicine, and medicine intermediary products.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.